ĀÜĄņĀŅĀ×

Dr. Scott Martin has 25 years of experience in bioanalytical/analytical mass spectrometry within drug discovery and development, predominately gained in large pharma. He has successfully supported projects throughout the drug discovery and development process by driving scientific innovation, matrix managing teams and providing expert opinion in the fields of biotransformation and bioanalysis. Before joining Domainex, Scott worked for AstraZeneca for 20 years as an associate principal scientist within the Oncology DMPK department. Previously, he has held positions in analytical/bioanalytical science at Roche, GlaxoWellcome, Zeneca agrochemicals and a large contract research organization (CRO).

While at AstraZeneca Scott successfully completed a part time PhD in drug metabolism entitled ā€˜Identification and Mechanistic Study of Novel Drug Metabolites by LC-MSā€™ at Sheffield Hallam University and has authored/co-authored 20 papers in peer reviewed journals.